No Data
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Incyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock. -- Barrons.com
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
Drugmaker Incyte Shares Fall 13% After Pausing CSU Study and Ending Pruritus Treatment
Incyte Faces Challenges but Remains Focused on Strategic Growth
Tuesday Market Falls, SMCI Flies, Big Box Retail Reports Mixed | Live Stock
No Data
No Data
